Blood collection ( DrugBank: - )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 229 | Autoimmune pulmonary alveolar proteinosis | 1 |
| 271 | Ankylosing spondylitis | 1 |
229. Autoimmune pulmonary alveolar proteinosis
Clinical trials : 44 / Drugs : 22 - (DrugBank : 7) / Drug target genes : 3 - Drug target pathways : 14
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04811274 (ClinicalTrials.gov) | June 7, 2021 | 19/3/2021 | Macrophages, GM-CSF and MARS Proteinosis | Study of Macrophage Function and of the GM-CSF Signaling Pathway in Alveolar Proteinosis by Mutations of the MARS Gene | Pulmonary Alveolar Proteinosis (PAP);MARS;Genetic Mutation | Biological: Blood collection;Biological: Bronchoalveolar lavage fluid collection | Assistance Publique - Hôpitaux de Paris | NULL | Recruiting | N/A | 17 Years | All | 20 | France |
271. Ankylosing spondylitis
Clinical trials : 574 / Drugs : 359 - (DrugBank : 68) / Drug target genes : 41 - Drug target pathways : 146
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02809300 (ClinicalTrials.gov) | November 2015 | 20/6/2016 | Ankylosing Spondylitis and Antiphospholipid Antibodies | Prevalence of Antiphospholipid Antibodies in Ankylosing Spondylitis: A Study of 80 Patients | Ankylosing Spondylarthritis | Biological: blood collection | CHU de Reims | NULL | Recruiting | 18 Years | N/A | Both | 80 | N/A | France |